Burning Rock Biotech (BNR) EBIT Margin (2019 - 2026)

Burning Rock Biotech (BNR) has reported EBIT Margin for 8 consecutive years, with 17.39% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT Margin fell 600.0% year-over-year to 17.39%; the TTM figure through Mar 2026 stood at 11.36% (up 3572.0% YoY), while the FY2025 annual figure was 10.17%, up 5915.0% from the prior year.
• EBIT Margin came in at 17.39% for Q1 2026 at Burning Rock Biotech, down from 9.53% in the prior quarter.
• The five-year high for EBIT Margin was 7.67% in Q2 2025, with the low at 206.08% in Q2 2022.
• Average EBIT Margin over 5 years is 90.78%, with a median of 92.79% recorded in 2023.
• Across the five-year window, EBIT Margin tumbled 4736 bps in 2022 and jumped 11329 bps in 2023, its largest moves.
• Year by year, EBIT Margin stood at 152.88% in 2022, then climbed by 10 bps to 137.37% in 2023, then surged by 53 bps to 65.01% in 2024, then surged by 85 bps to 9.53% in 2025, then sank by 82 bps to 17.39% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 17.39%, 9.53%, and 12.19% for Q1 2026, Q4 2025, and Q3 2025 respectively.